Oncologia.mx.- Personalized medicine is a global trend that our country has already reached and that can bring great benefits to the health sector. One of the health companies researching this topic is Roche Mexico, which organized the World DNA Day virtual panel called “Rewriting the History of Health, Patient by Patient”; where Bettina Zimmermann of Roche Farma Internacional, Dr. Carmen Aláez from the National Institute of Genomic Medicine (INMEGEN), Dr. Carlos Sorroza López, Senior Medical Advisor at IQVIA and Mtro. Kenji López from Cancer Warriors de México, AC
The goal of personalized medicine is to make diagnoses early and accurately so that each patient receives adequate treatment based on the specific origin of the disease, as well as quality assurance and care. One of the cases where good results have been achieved is in the field of oncology.
In her participation, Betina Zimmermann said that personalized medicine gives the right patient, at the right time, the right treatment. Personalized medicine allows patients to significantly improve their quality of life, “as not all patients are the same and there are some lines of treatment that benefit us.”
While the Mtro. Kenji López Cuevas said it is important for governments to consider the benefits of personalized medicine in order to better invest the budget and automate spending. “Consider the short- and long-term benefits of less hospitalization and patient recovery,” so he said it’s important to disseminate data, real-life experiences about these treatments.
He added that one of the main challenges is education, “the patient and decision makers must be able to have the arguments as to why these treatments should be implemented in the health sector in Mexico.”
Dr. Carlos Sorroza López said 8% of cancer treatment expenditure is for diagnosis, while 70% is allocated to treatments that often fail to benefit patients.
Meanwhile, Dr. Carmen Aláez spoke about the importance of biomarkers, since in regions prone to developing a particular disease, testing of young people is used to avoid late diagnosis and provide adequate treatment.
He added that patients with Mendelian diseases can benefit from these types of drugs today.
The experts agreed that it is everyone’s responsibility to promote the adoption of new ways to treat disease, in this sense it is important to enable patients to participate more actively in decision-making regarding their health, authorities and institutions, the constant updating of medical specialists, and the contribution of private initiative in relation to innovation and development of new diagnostic and treatment solutions.
At the end, Rachelle Neumann, communications leader for Roche Mexico, stressed: “It is important to convey the significance of this issue in the voices of various experts so that we can provide a complete overview of the current impact and evolution of personalized medicine, as adopting this approach presents a tremendous opportunity for more accurate diagnoses and treatments for the benefit of society as a whole ”.
It may interest you:
Only 28% of AML patients achieve a five-year survival rate
CMOM and Pfizer are working together to strengthen the knowledge of medical oncologists